Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShares IssuedShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBP) Change in Receivables (2017 - 2025)

Regen BioPharma (RGBP) has disclosed Change in Receivables for 8 consecutive years, with $27425.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables changed 0.0% to $27425.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $110001.0, a 0.0% change, with the full-year FY2025 number at $110000.0, up 15.94% from a year prior.
  • Change in Receivables was $27425.0 for Q4 2025 at Regen BioPharma, down from $27726.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $27726.0 in Q3 2021 to a low of -$122575.0 in Q4 2022.
  • A 5-year average of $5084.2 and a median of $27424.5 in 2021 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: crashed 546.95% in 2022, then skyrocketed 221.48% in 2024.
  • Regen BioPharma's Change in Receivables stood at $27425.0 in 2021, then plummeted by 546.95% to -$122575.0 in 2022, then soared by 110.03% to $12298.0 in 2023, then soared by 123.0% to $27424.0 in 2024, then rose by 0.0% to $27425.0 in 2025.
  • Per Business Quant, the three most recent readings for RGBP's Change in Receivables are $27425.0 (Q4 2025), $27726.0 (Q3 2025), and $27427.0 (Q2 2025).